NFA
NTLA icon

Nationwide Fund Advisors’s Intellia Therapeutics NTLA Stock Holding History

Nationwide Fund Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-8,048
Closed -$200K – 1398
2017
Q3 		$200K Hold
8,048
– – ﹤0.01% 2646
2017
Q2 		$129K Buy
8,048
+4,351
+118% +$60.8K ﹤0.01% 2800
2017
Q1 		$52K Sell
3,697
-842
-19% -$11.3K ﹤0.01% 2978
2016
Q4 		$60K Hold
4,539
– – ﹤0.01% 2983
2016
Q3 		$77K Hold
4,539
– – ﹤0.01% 2972
2016
Q2 		$97K Buy
+4,539
New +$121K ﹤0.01% 2927

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Nationwide Fund Advisors's NTLA Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Intellia Therapeutics (NTLA) in Q4 2017, closing a stake of 8,048 shares — an estimated $200K sold.

Nationwide Fund Advisors first reported a position in NTLA in Q2 2016 and held it in 6 quarters. The position peaked at $200K in Q3 2017. 112 funds tracked by Wall St. Rank hold NTLA as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Intellia Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 8,048 Intellia Therapeutics shares in Q4 2017, an estimated $200K.
  • Nationwide Fund Advisors first reported a position in Intellia Therapeutics in Q2 2016 and held it in 6 quarters.
  • Nationwide Fund Advisors's Intellia Therapeutics position peaked at $200K in Q3 2017.
  • 112 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.